Arthron Sales
This is what PRR and Southern Cross Equity Reported in Oct 2005:
Arthron (85%): Represents a next generation rheumatoid arthritis drug based on the FCƒ×RIIa receptor, a good upstream target for rheumatoid arthritis and a billion dollar a year market for ¡¥TNF non-responders¡¦. The Arthron technology is ready for licensing and is attracting interest from overseas Pharmas. We value Prima¡¦s interest in Arthron at $20.1m-$54m.
This is what PRR management achieved and was reported in the Lodge Report:
¡§About a year later, on 06 October 2005, Prima announced the sale of all Arthron assets to Trillium Therapeutics Inc. (Toronto, Canada). Prima received an up-front payment of US$500,000 and 7% equity stake in Trillium (currently valued by Prima at $A3.2m). Trillium is continuing all of Arthron¡¦s R&D collaborations and, as research milestones are met, Prima¡¦s share in Trillium could increase to 13%¡¨
So SCE valued Arthron at $20 to 50 million and Eugene and Marcus managed to do a deal a year later valued at $3.7 million now read on¡K¡K..
And now here¡¦s how PRR represented the deal at their 2006 AGM:
¡§That the Company approve the issue to Mr. Eugene Kopp of one hundred and seventy-eight
thousand one hundred and twenty five (178,125) ordinary shares in the capital of the
Company deemed fully paid at an issue price of eight and a half cents ($0.085) per share.¡¨
Subject to shareholders approval, Mr. Eugene Kopp will be issued a total of one hundred and seventy eight thousand one hundred and twenty-five (178,125) ordinary shares in the capital of the Company, fully paid at a deemed issue price of eight and one half cents ($0.085) each as a bonus associated with the Trillium Therapeutics transaction.
¡§That the Company approve the issue to Mr. Marcus Clark of seven hundred and twenty-four
thousand three hundred and seventy-five (724,375) ordinary shares in the capital of the
Company deemed fully paid at an issue price of eight and a half cents ($0.085) per share.¡¨
Subject to shareholders approval, Mr. Marcus Clark will be issued a total of seven hundred and
twenty-four thousand three hundred and seventy-five (724,375) ordinary shares in the capital of the Company, fully paid at a deemed issue price of eight and one half cents ($0.085) each as a bonus associated with the Trillium Therapeutics transaction.
These guys paid themselves a bonus for a serious reduction in shareholder value ¡V what a hide !
- Forums
- ASX - By Stock
- IMM
- lets talk about arthron
lets talk about arthron
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
35.5¢ |
Change
-0.015(4.05%) |
Mkt cap ! $526.5M |
Open | High | Low | Value | Volume |
36.5¢ | 37.0¢ | 35.5¢ | $191.7K | 532.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 66292 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.0¢ | 39866 | 16 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 65860 | 0.355 |
20 | 209960 | 0.350 |
15 | 71615 | 0.345 |
8 | 146090 | 0.340 |
8 | 93429 | 0.335 |
Price($) | Vol. | No. |
---|---|---|
0.360 | 39866 | 16 |
0.365 | 81727 | 11 |
0.370 | 93746 | 9 |
0.375 | 57405 | 6 |
0.380 | 124449 | 10 |
Last trade - 12.03pm 26/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online